We are live on ! Find out more
NGNE icon

Neurogene

63 hedge funds and large institutions have $21.4M invested in Neurogene in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.44% less ownership

Funds ownership: 2.89%2.45% (-0.44%)

22% less funds holding

Funds holding: 8163 (-18)

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

50% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 30

57% less capital invested

Capital invested by funds: $49.7M → $21.4M (-$28.3M)

Holders
63
Holders Change
-18
Holders Change %
-22.22%
% of All Funds
1.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
15
Reduced
22
Closed
30
Calls
$141K
Puts
Net Calls
+$141K
Net Calls Change
+$50K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$3.94M
RG
2
Redmile Group
California
$3.54M -$34.8K -1,425 -0.8%
Millennium Management
3
Millennium Management
New York
$2.18M +$1.07M +44,022 +71%
Renaissance Technologies
4
Renaissance Technologies
New York
$1.66M +$421K +17,265 +27%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.48M +$259K +10,621 +17%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.16M -$192K -7,865 -12%
BlackRock
7
BlackRock
New York
$938K -$2.01M -82,382 -64%
PAMS
8
Pictet Asset Management (Switzerland)
Switzerland
$805K -$2.19M -89,638 -70%
CS
9
Candriam SCA
Luxembourg
$805K
Morgan Stanley
10
Morgan Stanley
New York
$641K -$67.3K -2,761 -8%
OM
11
Opaleye Management
Massachusetts
$628K -$220K -9,000 -23%
Barclays
12
Barclays
United Kingdom
$466K -$6.95K -285 -1%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$399K +$120K +4,930 +34%
Two Sigma Investments
14
Two Sigma Investments
New York
$322K +$83.5K +3,425 +28%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$310K -$347K -14,236 -49%
ACM
16
ACT Capital Management
Pennsylvania
$205K
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$202K +$29.6K +1,215 +14%
Bank of America
18
Bank of America
North Carolina
$194K -$29.9K -1,225 -12%
E
19
Ergoteles
New York
$171K +$202K +8,298 New
RA
20
Royce & Associates
New York
$150K
KCM
21
Kynam Capital Management
New Jersey
$128K -$19.3K -790 -11%
State Street
22
State Street
Massachusetts
$126K -$565K -23,153 -79%
B
23
Bailard
California
$93K +$110K +4,505 New
JP Morgan Chase
24
JP Morgan Chase
New York
$88K +$70.7K +2,897 +210%
Citadel Advisors
25
Citadel Advisors
Florida
$82K +$72.2K +2,958 +291%

NGNE Hedge Fund Activity: Q2 2022 in Review

63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2022, worth a combined $21.4M — down 57% from $49.7M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of NGNE and 15 opened new positions — a net loss of 15 holders — while 22 trimmed existing stakes and 15 added.

The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $2.19M.

  • 63 institutional investors held Neurogene (NGNE) as of Q2 2022, down from 81 in Q1 2022.
  • Funds reported $21.4M of Neurogene stock for Q2 2022, down 57% quarter-over-quarter.
  • 15 funds opened new Neurogene positions in Q2 2022 and 30 closed out, a net change of -15 holders.
  • The largest Neurogene buyer in Q2 2022 was Millennium Management, an estimated $1.07M added.
  • The largest Neurogene seller in Q2 2022 was Pictet Asset Management (Switzerland), an estimated $2.19M sold.

Based on aggregated 13F filings for Q2 2022.